• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CD56 expression modulates NAD+ metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myeloma.

作者信息

Giorgetti Giulia, Maroto-Martin Elena, Soncini Debora, Fenoglio Daniela, Becherini Pamela, Benzi Andrea, Ravera Silvia, Traverso Isabella, Ladisa Francesco, Lai Francesco, Rivoli Giulia, Truffelli Dario, Nahimana Aimable, Cagnetta Antonia, Guolo Fabio, Uras Chiara R M, Schavgoulidze Anaïs, Fong Ng Jessica, Nencioni Alessio, Bruzzone Santina, Munshi Nikhil C, Lemoli Roberto Massimo, Fulciniti Mariateresa, Cea Michele

机构信息

Clinic of Hematology, Department of Internal Medicine and Medical Specialties (DiMI), University of Genoa, Genoa, Italy.

IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

出版信息

Blood Cancer J. 2025 May 2;15(1):83. doi: 10.1038/s41408-025-01284-y.

DOI:10.1038/s41408-025-01284-y
PMID:40316562
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12048669/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ad4/12048669/8d882f1e3b74/41408_2025_1284_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ad4/12048669/9ee916ac6426/41408_2025_1284_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ad4/12048669/c5c69181410b/41408_2025_1284_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ad4/12048669/8d882f1e3b74/41408_2025_1284_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ad4/12048669/9ee916ac6426/41408_2025_1284_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ad4/12048669/c5c69181410b/41408_2025_1284_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7ad4/12048669/8d882f1e3b74/41408_2025_1284_Fig3_HTML.jpg

相似文献

1
CD56 expression modulates NAD+ metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myeloma.CD56表达调节NAD+代谢格局并预测多发性骨髓瘤对抗CD38疗法的敏感性。
Blood Cancer J. 2025 May 2;15(1):83. doi: 10.1038/s41408-025-01284-y.
2
TNB-738, a biparatopic antibody, boosts intracellular NAD+ by inhibiting CD38 ecto-enzyme activity.TNB-738 是一种双靶向抗体，通过抑制 CD38 ecto-酶活性来提高细胞内 NAD+水平。
MAbs. 2022 Jan-Dec;14(1):2095949. doi: 10.1080/19420862.2022.2095949.
3
CD200 immune checkpoint expression is associated with inferior outcome in multiple myeloma patients treated with anti-CD38 monoclonal antibodies.CD200免疫检查点表达与接受抗CD38单克隆抗体治疗的多发性骨髓瘤患者的较差预后相关。
Oncoimmunology. 2025 Dec;14(1):2532226. doi: 10.1080/2162402X.2025.2532226. Epub 2025 Jul 20.
4
Downregulation of LATS1/2 Drives Endothelial Senescence-Associated Stemness (SAS) and Atherothrombotic Lesion Formation.LATS1/2的下调驱动内皮细胞衰老相关干性（SAS）和动脉粥样血栓形成病变的形成。
bioRxiv. 2025 Jun 21:2025.06.19.660635. doi: 10.1101/2025.06.19.660635.
5
Inhibition of CD38 by 78c Enhanced NAD, Alleviated Inflammation, and Decreased Oxidative Stress in Old Murine Macrophages Induced by Oral Pathogens.78c对CD38的抑制增强了老年小鼠巨噬细胞中由口腔病原体诱导的NAD水平，减轻了炎症并降低了氧化应激。
Int J Mol Sci. 2025 Jun 26;26(13):6180. doi: 10.3390/ijms26136180.
6
Daratumumab and isatuximab differentially affect CD38 detection on plasma cells in myeloma: Anti-CD38 nanobody (clone JK36) and CD319 combination improve flow cytometric identification of plasma cells after targeted therapies.达雷妥尤单抗和isatuximab对骨髓瘤浆细胞上CD38检测的影响不同：抗CD38纳米抗体（克隆JK36）和CD319组合可改善靶向治疗后浆细胞的流式细胞术鉴定。
Br J Haematol. 2025 Sep;207(3):757-766. doi: 10.1111/bjh.20218. Epub 2025 Jun 19.
7
Overcoming resistance to immunotherapy by targeting CD38 in human tumor explants.通过靶向人类肿瘤外植体中的CD38克服免疫治疗耐药性。
Cell Rep Med. 2025 Jul 15;6(7):102210. doi: 10.1016/j.xcrm.2025.102210. Epub 2025 Jun 27.
8
NAD glycohydrolases-CD38 as a therapeutic target in aging: physiological roles, molecular mechanisms, and future opportunities in anti-aging research.NAD糖水解酶-CD38作为衰老的治疗靶点：生理作用、分子机制及抗衰老研究的未来机遇
Biochem Pharmacol. 2025 Sep;239:117050. doi: 10.1016/j.bcp.2025.117050. Epub 2025 Jun 12.
9
[Detection of myeloma cells in the peripheral blood using flow cytometry].[运用流式细胞术检测外周血中的骨髓瘤细胞]
Vnitr Lek. 1997 Sep;43(9):592-8.
10
Unveiling the role of NAD glycohydrolase CD38 in aging and age-related diseases: insights from bibliometric analysis and comprehensive review.揭示烟酰胺腺嘌呤二核苷酸糖水解酶CD38在衰老及与年龄相关疾病中的作用：文献计量分析与综合综述的见解
Front Immunol. 2025 Jun 2;16:1579924. doi: 10.3389/fimmu.2025.1579924. eCollection 2025.

引用本文的文献

1
A rare dermatological manifestation of follicular spicules in a patient with multiple myeloma and end-stage renal disease on hemodialysis: A case report.一名患有多发性骨髓瘤和终末期肾病且正在接受血液透析的患者出现罕见的毛囊性棘状丘疹皮肤表现：病例报告。
Exp Ther Med. 2025 Jul 23;30(3):180. doi: 10.3892/etm.2025.12930. eCollection 2025 Sep.

本文引用的文献

1
NAD+ metabolism restriction boosts high-dose melphalan efficacy in patients with multiple myeloma.烟酰胺腺嘌呤二核苷酸（NAD+）代谢限制增强了大剂量美法仑对多发性骨髓瘤患者的疗效。
Blood Adv. 2025 Mar 11;9(5):1024-1039. doi: 10.1182/bloodadvances.2024013425.
2
CD56 expression predicts response to Daratumumab-based regimens.CD56表达可预测基于达雷妥尤单抗方案的疗效。
Blood Cancer J. 2024 Apr 12;14(1):62. doi: 10.1038/s41408-024-01051-5.
3
NSD2 drives t(4;14) myeloma cell dependence on adenylate kinase 2 by diverting one-carbon metabolism to the epigenome.
NSD2通过将一碳代谢导向表观基因组，驱动t(4;14)骨髓瘤细胞对腺苷酸激酶2的依赖。
Blood. 2024 Jul 18;144(3):283-295. doi: 10.1182/blood.2023022859.
4
Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma.CD38 抗体的免疫调节特性及其对多发性骨髓瘤抗癌疗效的影响。
Cancer Med. 2023 Oct;12(20):20332-20352. doi: 10.1002/cam4.6619. Epub 2023 Oct 15.
5
CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD-Lowering Agents.CD38诱导的代谢功能障碍使多发性骨髓瘤细胞对降低NAD的药物敏感。
Antioxidants (Basel). 2023 Feb 15;12(2):494. doi: 10.3390/antiox12020494.
6
Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.高危细胞遗传学的复发多发性骨髓瘤患者中伊沙妥昔单抗联合卡非佐米和地塞米松：IKEMA 亚组分析。
Eur J Haematol. 2022 Nov;109(5):504-512. doi: 10.1111/ejh.13835. Epub 2022 Aug 18.
7
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee.复发/难治性多发性骨髓瘤治疗中的差距和机遇：NCI 多发性骨髓瘤指导委员会的共识建议。
Blood Cancer J. 2022 Jun 29;12(6):98. doi: 10.1038/s41408-022-00695-5.
8
Redefining CD56 as a Biomarker and Therapeutic Target in Multiple Myeloma.重新定义 CD56 在多发性骨髓瘤中的生物标志物和治疗靶点。
Mol Cancer Res. 2022 Jul 6;20(7):1083-1095. doi: 10.1158/1541-7786.MCR-21-0828.
9
Targeting NAD Synthesis to Potentiate CD38-Based Immunotherapy of Multiple Myeloma.靶向 NAD 合成增强基于 CD38 的多发性骨髓瘤免疫治疗。
Trends Cancer. 2020 Jan;6(1):9-12. doi: 10.1016/j.trecan.2019.11.005. Epub 2019 Dec 31.
10
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.依沙佐米联合泊马度胺和低剂量地塞米松与泊马度胺和低剂量地塞米松治疗复发/难治性多发性骨髓瘤患者（ICARIA-MM）：一项随机、多中心、开放性、3 期研究。
Lancet. 2019 Dec 7;394(10214):2096-2107. doi: 10.1016/S0140-6736(19)32556-5. Epub 2019 Nov 14.